Medicare can now cover Eli Lilly’s Zepbound for sleep apnea, CMS says

Medicare can now cover Eli Lilly’s Zepbound for sleep apnea, CMS says


An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City on Dec. 11, 2023.

Brendan McDermid | Reuters

Medicare drug plans can now cover Eli Lilly‘s blockbuster obesity drug Zepbound for obstructive sleep apnea, CNBC confirmed on Wednesday. 

That opens the door for broader access to Zepbound, which is not currently covered by Medicare and many other insurance plans for weight loss. Demand for the injection has soared over the last year despite its roughly $1,000 price tag before insurance.

In a statement to CNBC, a spokesperson for the Centers for Medicare & Medicaid Services said “current Medicare Part D and Medicaid coverage rules apply” to Zepbound following its landmark approval last month for the most common sleep-related breathing disorder.

Medicare Part D plans can only cover obesity drugs if they are used for an additional medically accepted purpose approved by the Food and Drug Administration, the CMS spokesperson said, referring to the agency’s guidance. The spokesperson added that Part D plans may consider using prior authorization – a process where a provider must first get approval from an insurer – for those drugs to ensure they are being used for that specific purpose. 

The FDA on Dec. 20 cleared Zepbound for patients with obesity and moderate-to-severe forms of obstructive sleep apnea, or OSA, which refers to breathing interrupted during sleep due to narrowed or blocked airways. That made Zepbound the first drug treatment cleared for the estimated 20 million people with those forms of the disease, according to Eli Lilly.

Medicare Part D plans are similarly allowed to cover Novo Nordisk‘s weight loss drug Wegovy for its other approved use of lowering cardiovascular risks. The diabetes counterparts of Wegovy and Zepbound – Ozempic and Mounjaro, respectively – are covered by Medicare and most insurance plans. 

Both Novo Nordisk and Eli Lilly are studying their weight loss medicines as treatments for fatty liver disease, chronic kidney disease, sleep apnea and more. To be covered, those drugs would need to return late-stage trial results and then be submitted for FDA approval for those uses.

Meanwhile, state Medicaid coverage for Zepbound and other obesity medications depends on what condition they are prescribed for and whether their manufacturer has signed a certain Medicaid drug rebate agreement, according to the spokesperson. 

Under that agreement with the secretary of Health and Human Services, manufacturers agree to provide rebates to states in exchange for Medicaid coverage of their drugs. States share the rebates with the federal government. 

A state Medicaid program must cover Zepbound if it is prescribed for OSA and Eli Lilly has signed the Medicaid drug rebate agreement, the spokesperson said. 

But if Zepbound is prescribed for weight loss, state Medicaid programs are not required to cover it. 

The Biden administration in November proposed a rule that would allow Medicare and Medicaid to cover weight loss drugs for patients with obesity. The rule would give millions of people access to weekly injectables, but it would cost taxpayers as much as $35 billion over the next decade.

It is unclear if President-elect Donald Trump’s administration will pursue the rule.



Source

Startup Teal Health wins FDA approval for at-home test for cervical cancer screening
Health

Startup Teal Health wins FDA approval for at-home test for cervical cancer screening

The Food and Drug Administration on Friday approved the first-ever at-home test for cervical cancer screening, developed by San Francisco-based startup Teal Health. The company began developing the prototype for its Teal Wand just over five years ago. The concept was to make cervical cancer screening more accessible via telehealth and a test that could […]

Read More
These 6 portfolio names pledged big U.S. investments since Trump took office again
Health

These 6 portfolio names pledged big U.S. investments since Trump took office again

Many of the biggest U.S. companies have pledged to invest trillions of dollars in the United States since President Donald Trump started his second term — including six names in our portfolio. These moves are aimed at aligning companies with the president’s vision for a new global trade order designed to bring manufacturing jobs back […]

Read More
UnitedHealthcare sued by shareholders over reaction to CEO’s killing
Health

UnitedHealthcare sued by shareholders over reaction to CEO’s killing

Brian Thompson, CEO of UnitedHealthcare. Courtesy: UnitedHealth Group A group of investors sued UnitedHealthcare Group on Wednesday, accusing the company of misleading them after the killing of its CEO, Brian Thompson. The class action lawsuit — filed in the Southern District of New York — accuses the health insurance company of not initially adjusting their 2025 […]

Read More